MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm

Core Viewpoint - Myriad Genetics, Inc. is under investigation following the announcement that UnitedHealth Group will cease coverage of its GeneSight genetic test, leading to a significant drop in Myriad's stock price [2]. Group 1: Investigation Details - On October 31, 2024, UnitedHealth Group announced it would no longer cover GeneSight, effective January 1, 2025, citing that tests for behavioral health, including GeneSight, are "unproven" and "not medically necessary" [2]. - Following this announcement, Myriad's stock price experienced a sharp decline during intraday trading on November 1, 2024 [2]. Group 2: Legal Representation - Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad securities and encourages affected investors to participate in the investigation [1][3]. - The firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorneys' fees if successful in court [3]. Group 3: Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors [4].